The in vitro antifungal susceptibilities of 159 clinical isolates of Candida species from patients with invasive candidiasis in Kuala Lumpur Hospital, Malaysia, were determined against amphotericin B, fluconazole, voriconazole, itraconazole and caspofungin. The most common species were Candida albicans (71 isolates), Candida parapsilosis (42 isolates), Candida tropicalis (27 isolates) and Candida glabrata (12 isolates). The susceptibility tests were carried out using an E-test. The MIC breakpoints were based on Clinical Laboratory Standards Institute criteria. Amphotericin B and voriconazole showed the best activities against all the isolates tested, with MIC 90 values of ¡1 mg ml "1 for all major species. Only one Candida lusitaniae isolate was resistant to amphotericin B, and all the isolates were susceptible to voriconazole. In total, six isolates were resistant to fluconazole, comprising two isolates of C. albicans, two of C. parapsilosis, one C. tropicalis and one C. glabrata, and all of these isolates showed cross-resistance to itraconazole. The MIC 90 of itraconazole was highest for C. glabrata and C. parapsilosis. Caspofungin was active against most of the isolates except for five isolates of C. parapsilosis. The MIC 90 of caspofungin against C. parapsilosis was 3 mg ml "1 . In conclusion, amphotericin B remains the most active antifungal agent against most Candida species except for C. lusitaniae. Voriconazole is the best alternative for fluconazole-or itraconizole-resistant isolates. Although five of the C. parapsilosis isolates showed in vitro resistance to caspofungin, more clinical correlation studies need to be carried out to confirm the significance of these findings. Currently, despite the increase in usage of antifungals in our hospitals, especially in the management of febrile neutropenia patients, the antifungal-resistance problem among clinically important Candida isolates in Kuala Lumpur Hospital is not yet worrying. However, continued antifungal-susceptibility surveillance needs to be conducted to monitor the antifungalsusceptibility trends of Candida species and other opportunistic fungal pathogens.
INTRODUCTION
Candida species have emerged as a significant cause of morbidity and mortality worldwide over the past few decades, accounting for approximately 15 % of all hospitalacquired infections, .72 % of all nosocomial fungal infections and 8-15 % of all nosocomial bloodstream infections (BSIs) (Blot et al., 2008; Edmond et al., 1999; Wenzel & Edmond, 2001) . Between 25 and 50 % of nosocomial candidaemia cases occur in critical care units (Rangel-Frausto et al., 1999) . Among the major risk factors for developing systemic candidiasis in cancer patients are neutropenia and chemotherapy-induced gut-wall injuries, whilst in non-cancer patients the most significant risk factors are the presence of catheters, gut-wall surgery and prematurity (Bodey et al., 2002; Pfaller et al., 1998a; Wenzel & Edmond, 2001) . Analysis of secular trends in epidemiology and microbiology of nosocomial BSIs in the USA was made using nationwide surveillance data from the SCOPE (Surveillance and Control of Pathogens of Epidemiological Importance) survey, and Candida species were shown to be the fourth most common cause of nosocomial BSIs, accounting for 9 % of all cases of BSI in hospitals in the USA (Pfaller et al., 1998b) . The crude mortality rate of BSIs due to Candida species was 39.2 %, the highest among all other blood isolates (Wisplinghoff et al., 2004) . There are few reports of Candida species distribution in Malaysia and their biotypes and genetic relatedness (Chong et al., 2003; Ng et al., 1998) , and reports on antifungal susceptibilities of Candida species towards the commonly used antifungal are not readily available.
In this study, we analysed the antifungal susceptibilities of Candida species isolated from sterile clinical samples of hospitalized patients admitted to Kuala Lumpur Hospital from January 2006 to December 2008.
METHODS
Candida isolates. Candida spp. isolated from sterile clinical samples of patients with invasive candidiasis were collected. The isolates were from patients admitted to Kuala Lumpur Hospital from January 2006 to December 2008. Most of the samples were from blood (77 %) and peritoneal dialysis fluid (10 %). Other samples (13 %) were urine, bronchoalveolar lavage and cerebrospinal fluid. All isolates were identified to the species level using conventional as well as a commercial biochemical identification kit (API 20C AUX; bioMérieux).
Antifungal-susceptibility tests. In vitro antifungal-susceptibility tests were conducted on all the Candida isolates using an E-test (AB Biodisk). Instructions provided by the manufacturer were adhered to throughout the tests. The antifungals tested in this study were amphotericin B (range 0.002-32 mg ml 21 ), fluconazole (0.016-256 mg ml 21 ), itraconazole (0.002-32 mg ml 21 ), voriconazole (0.002-32 mg ml 21 ) and caspofungin (0.002-32 mg ml 21 ).
Yeast suspensions were prepared in 0.85 % NaCl. The turbidity of each suspension was adjusted to a 0.5 McFarland standard. Using cotton-tipped swabs, each organism suspension was inoculated onto agar plates containing RPMI 1640 supplemented with 2 % glucose and buffered to pH 7.0 with MOPS. After application of the E-test strips, the plates were incubated for 48 h at 35 uC. The MIC of each isolate against each antifungal tested was read after 24 and 48 h.
Reference isolates Candida albicans ATCC 90028 and Candida parapsilosis ATCC 22019 T were used as controls. Interpretive susceptibility criteria recommended by the Clinical and Laboratory Standards Institute (CLSI) were used to evaluate the susceptibilities of isolates against fluconazole, itraconizole, voriconazole and caspofungin. For fluconazole, isolates showing an MIC of ¡8.0 mg ml 21 were regarded as susceptible, 16-32 mg ml 21 as susceptible dose-dependent (SDD) and ¢64 mg ml 21 as resistant. For itraconazole, isolates with an MIC of ¡0.125 mg ml 21 were regarded as susceptible, 0.25-0.5 mg ml 21 as SDD and ¢1 mg ml 21 as resistant. For voriconazole, isolates with an MIC of ¡1.0 mg ml 21 were regarded as susceptible, 2.0 mg ml 21 as SDD and ¢4 mg ml 21 as resistant (CLSI, 2008; Ostrosky-Zeichner et al., 2003) . Isolates with an MIC of ¡2.0 mg ml 21 were considered susceptible to caspofungin. Due to the lack of defined breakpoint for amphotericin B, isolates showing an MIC of ¡1.0 mg ml 21 were taken as susceptible and those with an MIC of .2 mg ml 21 were considered resistant (Ostrosky-Zeichner et al., 2003; Rex et al., 1997) .
RESULTS
A total of 159 Candida isolates were collected and tested. They comprised 71 isolates of C. albicans, 42 isolates of C. parapsilosis, 27 isolates of Candida tropicalis, 12 isolates of Candida glabrata, two isolates of Candida guilliermondii, two isolates of Candida famata, one strain of Candida inconspicua, one strain of Candida valida and one strain of Candida lusitaniae. The distribution of the isolates by wards is shown in Table 1 . Most of the C. albicans isolates (66/71, 92 %) were isolated from non-neutropenic patients.
Antifungal-susceptibility tests were performed on all the clinical isolates collected. All the organisms tested produced detectable growth by 48 h. The MIC ranges and MIC 90 values of the five antifungal drugs against C. albicans, C. parapsilosis, C. tropicalis and C. glabrata are summarized in Table 2 . The percentage susceptibilities of C. albicans, C. parapsilosis, C. tropicalis and C. glabrata are shown in Table 3 . For the other Candida species, the number of isolates was too low for full analyses to be performed.
The MIC 90 values of amphotericin B against C. albicans, C. parapsilosis, C. tropicalis and C. glabrata were all ¡1 mg ml 21 . All isolates except for the single isolate of C. lusitaniae (MIC 4 mg ml 21 ) were susceptible to amphotericin B. The MIC 90 values of fluconazole for C. albicans, C. parapsilosis, C. tropicalis and C. glabrata were 8, 4, 0.75 and 16 mg ml 21 , respectively. The percentage susceptibilities 
DISCUSSION
During the study period, a total of 159 Candida isolates from systemic candidiasis cases were collected and their in vitro antifungal susceptibilities were analysed. Almost half (44.7 %) of the isolates were C. albicans, followed by C. parapsilosis (26.4 %). This is consistent with most published reports, where C. albicans has been the predominant species isolated from cases of systemic candidiasis (Kao et al., 1999; Mokaddas et al., 2007; Morgan, 2005) . The emergence of infections due to non-albicans Candida species has been noted particularly among neutropenic patients (Kao et al., 1999) . In this study, 82 % of all Candida isolates from patients admitted to the adult and paediatric haematology, oncology and bone-marrow transplant wards were non-albicans Candida species.
Antimicrobial-surveillance programmes have provided useful information regarding resistant trends and can be used as guidance for empirical therapy. However, most surveillance programmes focus only on bacterial pathogens and seldom emphasize fungal pathogens. In Malaysia, for example, surveillance does not include surveys on the antifungal resistance of opportunistic fungal pathogens. The present study was conducted to obtain basic data on the distribution of systemic candidiasis and the antifungal-susceptibility patterns of the clinically important Candida species in Kuala Lumpur Hospital, Malaysia. The in vitro activities of Candida species against amphotericin B, fluconazole, itraconazole, voriconazole and caspofungin have been reported in several studies (Anaissie et al., 1996; Pfaller et al., 2005 Pfaller et al., , 2008 .
In this study, amphotericin B showed good activity against all the isolates, with MIC 90 values of ¡1 mg ml 21 for all major isolates. In fact, all the isolates were susceptible except for C. lusitaniae. The level of fluconazole resistance among the isolates tested was relatively low, similar to that found in other studies (Pfaller et al., 2005; Ostrosky-Zeichner et al., 2003; Ruan et al., 2008) . Only a few isolates of C. albicans (two), C. parapsilosis (two), C. tropicalis (one) and C. glabrata (one) were resistant to fluconazole and all of these isolates showed cross-resistance to itraconazole. Therefore, fluconazole can still be used as a first-line therapy for infections caused by Candida species other than C. glabrata and C. krusei. The percentage susceptibility of C. glabrata isolates to fluconazole in this study was 83.4 %. However, because of the low number of isolates (n512), it is not justifiable to say that there is high prevalence of fluconazole-resistant C. glabrata in this hospital. It is interesting to note that, despite the wide usage of fluconazole over the past decade, emergence of C. krusei infections due to selective pressure has not occurred, in contrast to the findings observed in other reports (Ruan et al., 2008) . The MIC 90 values for itraconazole were highest for C. glabrata and C. parapsilosis.
Voriconazole had the best activity (MIC 90 ¡1 mg ml 21 ) against all the isolates tested. Cross-resistance was not demonstrated between the older azoles and voriconazole, making it a good alternative agent against isolates that are resistant to the older azoles.
In vitro resistance of C. parapsilosis to caspofungin has been reported in several studies (Mora-Duarte et al., 2002; Forrest et al., 2008) . However, Pfaller et al. (2006) reported that the caspofungin MIC distribution remains unchanged for Candida isolates, including C. parapsilosis collected before and after the introduction of caspofungin into clinical use (Anaissie et al., 1996) . Because of the slightly higher prevalence of resistance among C. parapsilosis to caspofungin, there have been reports of breakthrough infection of C. parapsilosis whilst patients were on caspofungin (Forrest et al., 2008; Cheung et al., 2006) . In another study, there was a significant increase in C. parapsilosis infections following extensive usage of caspofungin as an empirical and prophylactic antifungal agent (Forrest et al., 2008) . In the present study, the MIC 90 of caspofungin against C. parapsilosis was 3 mg ml 21 . Five isolates were resistant and three of them had MICs of .32 mg ml 21 .
In conclusion, amphotericin B remains the most active antifungal agent against most Candida species except for C. lusitaniae. Fluconazole can still be used as a first-line empirical antifungal agent except in settings where the majority of isolates are C. glabrata. Voriconazole is the best alternative for fluconazole-and itraconizole-resistant isolates. The findings of in vitro resistance of C. parapsilosis against caspofungin need to be studied further to define its clinical significance. Antifungal-susceptibility testing should be carried out routinely for all invasive infections caused by Candida species and other opportunistic fungal pathogens to monitor epidemiological trends and to detect the emergence of antifungal resistance.
